These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

307 related items for PubMed ID: 24704029

  • 1. Tetra-substituted imidazoles as a new class of inhibitors of the p53-MDM2 interaction.
    Vaupel A, Bold G, De Pover A, Stachyra-Valat T, Lisztwan JH, Kallen J, Masuya K, Furet P.
    Bioorg Med Chem Lett; 2014 May 01; 24(9):2110-4. PubMed ID: 24704029
    [Abstract] [Full Text] [Related]

  • 2. Small-molecule MDM2-p53 inhibitors: recent advances.
    Zhang B, Golding BT, Hardcastle IR.
    Future Med Chem; 2015 May 01; 7(5):631-45. PubMed ID: 25921402
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Design, synthesis, and biological evaluation of imidazoline derivatives as p53-MDM2 binding inhibitors.
    Hu C, Li X, Wang W, Zhang L, Tao L, Dong X, Sheng R, Yang B, Hu Y.
    Bioorg Med Chem; 2011 Sep 15; 19(18):5454-61. PubMed ID: 21855354
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Synthesis and evaluation of novel orally active p53-MDM2 interaction inhibitors.
    Miyazaki M, Naito H, Sugimoto Y, Yoshida K, Kawato H, Okayama T, Shimizu H, Miyazaki M, Kitagawa M, Seki T, Fukutake S, Shiose Y, Aonuma M, Soga T.
    Bioorg Med Chem; 2013 Jul 15; 21(14):4319-31. PubMed ID: 23685175
    [Abstract] [Full Text] [Related]

  • 14. A Unique Mdm2-Binding Mode of the 3-Pyrrolin-2-one- and 2-Furanone-Based Antagonists of the p53-Mdm2 Interaction.
    Surmiak E, Twarda-Clapa A, Zak KM, Musielak B, Tomala MD, Kubica K, Grudnik P, Madej M, Jablonski M, Potempa J, Kalinowska-Tluscik J, Dömling A, Dubin G, Holak TA.
    ACS Chem Biol; 2016 Dec 16; 11(12):3310-3318. PubMed ID: 27709883
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Lead optimization of novel p53-MDM2 interaction inhibitors possessing dihydroimidazothiazole scaffold.
    Miyazaki M, Naito H, Sugimoto Y, Kawato H, Okayama T, Shimizu H, Miyazaki M, Kitagawa M, Seki T, Fukutake S, Aonuma M, Soga T.
    Bioorg Med Chem Lett; 2013 Feb 01; 23(3):728-32. PubMed ID: 23266121
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Design, synthesis and biological evaluation of novel 3,4,5-trisubstituted aminothiophenes as inhibitors of p53-MDM2 interaction. Part 1.
    Wang W, Shangguan S, Qiu N, Hu C, Zhang L, Hu Y.
    Bioorg Med Chem; 2013 Jun 01; 21(11):2879-85. PubMed ID: 23601819
    [Abstract] [Full Text] [Related]

  • 20. Efficient reactivation of p53 in cancer cells by a dual MdmX/Mdm2 inhibitor.
    Qin L, Yang F, Zhou C, Chen Y, Zhang H, Su Z.
    J Am Chem Soc; 2014 Dec 31; 136(52):18023-33. PubMed ID: 25453499
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.